Published in Clin Gastroenterol Hepatol on July 14, 2006
Exploring utilities and outcomes with infliximab therapy. Clin Gastroenterol Hepatol (2006) 2.04
Inflammatory bowel disease: past, present, and future. J Gastroenterol (2007) 1.83
Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol (2008) 1.52
Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol (2010) 1.09
The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch Arztebl Int (2009) 1.07
Predicting response to Anti-TNF Agents for the treatment of crohn's disease. Therap Adv Gastroenterol (2009) 0.96
An old herbal medicine with a potentially new therapeutic application in inflammatory bowel disease. Int J Clin Exp Med (2011) 0.90
Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion (2009) 0.87
Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient (2013) 0.87
Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol (2011) 0.85
Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut (2007) 0.82
Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach. World J Gastroenterol (2008) 0.80
Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol (2010) 0.80
Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease. World J Gastroenterol (2014) 0.76
Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol (2015) 0.75
Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model. Inflamm Bowel Dis (2013) 0.75
Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease. Prz Gastroenterol (2015) 0.75
Infliximab: the evidence for its place in therapy in ulcerative colitis. Core Evid (2008) 0.75
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 5.66
Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology (2003) 5.42
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med (2012) 4.72
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA (2004) 4.36
A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology (2013) 4.06
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology (2011) 3.84
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol (2006) 2.97
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy. Clin Gastroenterol Hepatol (2008) 2.74
Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet (2002) 2.74
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol (2009) 2.72
Paraesophageal hernias: operation or observation? Ann Surg (2002) 2.71
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst (2004) 2.53
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst (2012) 2.30
Implications and cost of pancreatic leak following distal pancreatic resection. Arch Surg (2006) 2.25
Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the "test-of-time approach". Cancer (2003) 2.22
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology (2005) 2.05
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
The risk of developing Crohn's disease after an appendectomy: a meta-analysis. Am J Gastroenterol (2008) 1.74
Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology (2007) 1.71
Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS One (2012) 1.66
Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes. Cancer Biol Ther (2006) 1.63
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology (2007) 1.60
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology (2012) 1.58
Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis (2006) 1.58
Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J Med Microbiol (2009) 1.58
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol (2008) 1.57
Abdominopelvic CT increases diagnostic certainty and guides management decisions: a prospective investigation of 584 patients in a large academic medical center. AJR Am J Roentgenol (2011) 1.56
Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology (2008) 1.56
Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med (2012) 1.52
Reorganizing the system of care surrounding laparoscopic surgery: a cost-effectiveness analysis using discrete-event simulation. Med Decis Making (2004) 1.51
Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics (2009) 1.48
Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus. Dig Dis Sci (2014) 1.44
Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis (2010) 1.42
Staging MR lymphangiography of the axilla for early breast cancer: cost-effectiveness analysis. AJR Am J Roentgenol (2008) 1.42
Cost-effectiveness of coronary MDCT in the triage of patients with acute chest pain. AJR Am J Roentgenol (2008) 1.37
A systematic meta-analysis of the efficacy and heterogeneity of disease management programs in congestive heart failure. J Card Fail (2006) 1.36
Clinical outcomes and cost-effectiveness of coronary computed tomography angiography in the evaluation of patients with chest pain. J Am Coll Cardiol (2009) 1.34
Calibration of disease simulation model using an engineering approach. Value Health (2009) 1.27
Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer (2008) 1.26
Cost-effectiveness of whole-body CT screening. Radiology (2005) 1.25
Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol (2004) 1.25
Utility estimates for decision-analytic modeling in chronic heart failure--health states based on New York Heart Association classes and number of rehospitalizations. Value Health (2008) 1.24
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis (2011) 1.22
Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists. J Pediatr Gastroenterol Nutr (2009) 1.22
Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value Health (2011) 1.22
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol (2012) 1.22
Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease. Am J Gastroenterol (2006) 1.21
The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol (2010) 1.19
Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts. BMJ (2013) 1.18
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15
Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology (2012) 1.15
Estimation of mortality rates for disease simulation models using Bayesian evidence synthesis. Med Decis Making (2006) 1.14
Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology (2002) 1.14
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis (2011) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis. Radiology (2008) 1.13
Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal (2008) 1.13
Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.13
Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer (2014) 1.13
Diagnostic imaging costs: are they driving up the costs of hospital care? Radiology (2005) 1.11
Long-term acceptance of renal allografts following prenatal inoculation with adult bone marrow. Transplantation (2005) 1.11
Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model. Radiology (2002) 1.11
Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm (2010) 1.11
Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur J Pediatr (2002) 1.11
Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol (2012) 1.09
Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers. Radiology (2010) 1.09
Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J Clin Oncol (2007) 1.09
Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg (2008) 1.09
Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis. Radiology (2010) 1.07
Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Dig Dis Sci (2003) 1.07
Probiotics for recurrent Clostridium difficile disease. J Med Microbiol (2005) 1.06
Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases. Am J Gastroenterol (2013) 1.05
Risk factors for colorectal cancer in Crohn's colitis: a case-control study. Inflamm Bowel Dis (2006) 1.05
Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal (2012) 1.05
Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis. Radiology (2008) 1.04
Elective endovascular versus open surgical repair of abdominal aortic aneurysms: systematic review of short-term results. Radiology (2002) 1.03
Radiofrequency ablation: Effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model. J Vasc Interv Radiol (2004) 1.03
Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer (2010) 1.01
Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival. Gastrointest Endosc (2010) 1.00
Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials? Inflamm Bowel Dis (2012) 1.00